Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
November 13, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4...
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
November 06, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended September 30, 2024, and provided a business update.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
October 24, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new patient-reported outcome data demonstrating that ZORYVE cream 0.15% improved the impact of AD on patients and families.
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
October 23, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Quarterly investor conference call and webcast is scheduled for Wednesday, November 6 at 4:30 p.m. ETArcutis management will also participate in the Guggenheim Securities Healthcare Innovation...
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
October 18, 2024 08:20 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
September 25, 2024 01:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials.
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
September 24, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3% for scalp and body psoriasis.
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
September 19, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
ZORYVE® (roflumilast) cream 0.15% improved atopic dermatitis (AD) across multiple efficacy endpoints while demonstrating favorable safety and tolerabilityAcross both studies, approximately 31% of...